Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets BCR‑ABL positive leukemic cells and is indicated for the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients. It is marketed within the European Union and complies with GMP standards.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics across multiple continents worldwide, with consistent quality assurance.

Nilotinib acts on the BCR‑ABL tyrosine kinase pathway, providing targeted therapy for specific leukemias.

Chronic myeloid leukemia (CML): reduces disease progression and improves survival in adult patients. Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission when combined with chemotherapy. Accelerated‑phase CML: achieves cytogenetic response where earlier therapies have failed.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools often occurring early in therapy. - Rash: skin erythema that may be pruritic. - Fatigue: generalized tiredness without exertion.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: severe abdominal pain with elevated enzymes. - Hepatic injury: marked elevation of liver transaminases and bilirubin.

Nilotinib requires careful monitoring and patient education before and during therapy. - Cardiac monitoring: assess baseline ECG and repeat periodically for QT prolongation. - Blood glucose: monitor fasting glucose and HbA1c as hyperglycemia can occur. - Hepatic function: check liver enzymes before initiation and during treatment. - Drug interactions: avoid strong CYP3A4 inhibitors that can increase exposure. - Caution in patients with pre‑existing QT prolongation or electrolyte disturbances. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nilotinib has a notable potential for drug‑drug interactions that may alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - Diuretics (especially potassium‑sparing): affect electrolyte balance and QT interval. - Warfarin: monitor INR as nilotinib can alter anticoagulant effect.